Gary Wild

10.6k total citations · 4 hit papers
144 papers, 7.7k citations indexed

About

Gary Wild is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Gary Wild has authored 144 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Genetics, 57 papers in Epidemiology and 48 papers in Surgery. Recurrent topics in Gary Wild's work include Inflammatory Bowel Disease (72 papers), Microscopic Colitis (46 papers) and Helicobacter pylori-related gastroenterology studies (23 papers). Gary Wild is often cited by papers focused on Inflammatory Bowel Disease (72 papers), Microscopic Colitis (46 papers) and Helicobacter pylori-related gastroenterology studies (23 papers). Gary Wild collaborates with scholars based in Canada, Hungary and United States. Gary Wild's co-authors include Richard N. Fedorak, Brian G. Feagan, Gordon R. Greenberg, John WD McDonald, Stephen B. Hanauer, Paul Rutgeerts, A. Hillary Steinhart, Alain Bitton, A. B. R. Thomson and Albert Cohen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Gary Wild

135 papers receiving 7.4k citations

Hit Papers

Infliximab Maintenance Th... 1995 2026 2005 2015 2004 1995 2005 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
    2004 1.6k citations Bruce E. Sands, Frank Anderson et al. New England Journal of Medicine profile →
  2. Methotrexate for the Treatment of Crohn's Disease
    1995 651 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →
  3. Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
    2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →
  4. A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
    2000 530 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gary Wild 5.3k 3.8k 2.1k 1.7k 644 144 7.7k
A. Hillary Steinhart 6.5k 1.2× 5.1k 1.3× 2.3k 1.1× 1.5k 0.9× 642 1.0× 146 8.5k
Walter Reinisch 5.6k 1.1× 4.1k 1.1× 2.0k 0.9× 2.0k 1.1× 1.1k 1.6× 223 8.1k
Jean–Frédéric Colombel 7.0k 1.3× 5.5k 1.4× 2.7k 1.3× 1.6k 0.9× 752 1.2× 75 8.9k
Subra Kugathasan 5.1k 1.0× 3.4k 0.9× 2.2k 1.0× 1.7k 1.0× 1.2k 1.9× 175 7.8k
Adam S. Cheifetz 4.9k 0.9× 3.6k 0.9× 1.9k 0.9× 2.3k 1.3× 548 0.9× 213 7.7k
Gionata Fiorino 4.5k 0.8× 3.3k 0.9× 1.9k 0.9× 1.9k 1.1× 656 1.0× 255 7.0k
Fernando Magro 5.5k 1.0× 4.2k 1.1× 2.4k 1.2× 1.5k 0.9× 1.1k 1.6× 307 8.6k
Johanna C. Escher 4.0k 0.8× 2.7k 0.7× 2.2k 1.1× 1.2k 0.7× 685 1.1× 164 6.9k
Frank M. Ruemmele 5.1k 1.0× 3.3k 0.9× 3.5k 1.6× 2.2k 1.3× 1.0k 1.6× 156 9.9k
Richard K. Russell 5.2k 1.0× 3.3k 0.9× 2.7k 1.3× 1.3k 0.7× 1.3k 2.0× 188 7.6k

Countries citing papers authored by Gary Wild

Since Specialization
Citations

This map shows the geographic impact of Gary Wild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Wild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Wild more than expected).

Fields of papers citing papers by Gary Wild

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Wild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Wild. The network helps show where Gary Wild may publish in the future.

Co-authorship network of co-authors of Gary Wild

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Wild. A scholar is included among the top collaborators of Gary Wild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Wild. Gary Wild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lakatos, Péter L., Victoria Marcus, Waqqas Afif, et al.. (2025). Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 31(11). 2977–2985.
2.
Solitano, Virginia, Gary Wild, Péter L. Lakatos, et al.. (2025). P0595 Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experience. Journal of Crohn s and Colitis. 19(Supplement_1). i1185–i1185.
3.
Afif, Waqqas, Alain Bitton, Gary Wild, et al.. (2024). P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience. Journal of Crohn s and Colitis. 18(Supplement_1). i1337–i1337. 1 indexed citations
4.
Wetwittayakhlang, Panu, Christine Verdon, Michael Starr, et al.. (2023). Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. The Turkish Journal of Gastroenterology. 34(6). 603–610. 1 indexed citations
5.
Wetwittayakhlang, Panu, Waqqas Afif, Gary Wild, et al.. (2023). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. 56(1). 35–42. 10 indexed citations
6.
Restellini, Sophie, Alain Bitton, Gary Wild, et al.. (2023). Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases. Crohn s & Colitis 360. 5(1). otad004–otad004. 4 indexed citations
7.
8.
Wetwittayakhlang, Panu, Petra A. Golovics, Alex Al Khoury, et al.. (2022). Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. Journal of Gastrointestinal and Liver Diseases. 31(4). 403–410. 2 indexed citations
9.
Golovics, Petra A., Lóránt Gönczi, Christine Verdon, et al.. (2021). P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study. Journal of Crohn s and Colitis. 15(Supplement_1). S381–S382.
10.
Wetwittayakhlang, Panu, Petra A. Golovics, Talat Bessissow, et al.. (2021). Clinical Outcomes of COVID‐19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology. 2021(1). 7591141–7591141. 17 indexed citations
11.
Khoury, Alex Al, Petra A. Golovics, Rita Kohen, et al.. (2021). Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Digestive and Liver Disease. 53(8). 980–986. 5 indexed citations
12.
Khoury, Alex Al, Zsuzsanna Kürti, Lóránt Gönczi, et al.. (2020). The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center. Journal of Gastrointestinal and Liver Diseases. 29(4). 555–559. 5 indexed citations
13.
Gönczi, Lóránt, Zsuzsanna Kürti, Isabelle Morin, et al.. (2020). Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World Journal of Gastroenterology. 26(7). 759–769. 10 indexed citations
14.
Reinglas, Jason, Lóránt Gönczi, Christine Verdon, et al.. (2019). Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Digestive Diseases and Sciences. 65(7). 2046–2053. 12 indexed citations
15.
Thiesen, Aducio, Kelly A. Tappenden, Michael I. McBurney, et al.. (2008). Dietary Lipids Alter the Effect of Steroids on the Transport of Fructose Following Intestinal Resection in Rats. Digestive Diseases and Sciences. 53(8). 2126–2139.
16.
Sands, Bruce E., Frank Anderson, Çharles N. Bernstein, et al.. (2004). Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine. 350(9). 876–885. 1607 indexed citations breakdown →
17.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2003). A RANDOMIZED CONTROLLED TRIAL OF A HUMANIZED ALPHA4BETA7 ANTIBODY IN ULCERATIVE COLITIS (UC). The American Journal of Gastroenterology. 98. S248–S249. 4 indexed citations
18.
Thomson, A. B. R., M. Keelan, Aducio Thiesen, et al.. (2001). REVIEW: Small Bowel Review: Diseases of the Small Intestine. Digestive Diseases and Sciences. 46(12). 2555–2566. 36 indexed citations
19.
Fedorak, Richard N., Alfred Gangl, Charles O. Elson, et al.. (2000). Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology. 119(6). 1473–1482. 386 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Hillary Steinhart Breakdown of academic impact, for papers by Walter Reinisch Breakdown of academic impact, for papers by Jean–Frédéric Colombel Breakdown of academic impact, for papers by Subra Kugathasan Breakdown of academic impact, for papers by Adam S. Cheifetz Breakdown of academic impact, for papers by Gionata Fiorino Breakdown of academic impact, for papers by Fernando Magro Breakdown of academic impact, for papers by Johanna C. Escher Breakdown of academic impact, for papers by Frank M. Ruemmele Breakdown of academic impact, for papers by Richard K. Russell
Rankless by CCL
2026